Wyszuk. zaawans.

Tom 7, Nr 3 (2022)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2022-06-23
Dodaj do koszyka: 49,00 PLN
Wyświetlenia strony 4698
Wyświetlenia/pobrania artykułu 1073
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Diagnostyka i postępowanie w ciążach wielopłodowych powikłanych ograniczeniem wzrastania płodu — rekomendacje Polskiego Towarzystwa Ginekologów i Położników

Katarzyna Kosińska-Kaczyńska1, Andrzej Torbé2, Sebastian Kwiatkowski2, Dariusz Borowski34, Grzegorz Breborowicz5, Krzysztof Czajkowski6, Bartosz Czuba7, Hubert Huras8, Katarzyna Janiak9, Anna Kajdy10, Jarosław Kalinka11, Przemysław Kosiński4, Bożena Leszczyńska-Gorzelak12, Radzisław Mierzyński12, Mariola Ropacka-Lesiak5, Piotr Sieroszewski11, Małgorzata Świątkowska-Freund13, Mirosław Wielgoś4, Mariusz Zimmer14
Ginekologia i Perinatologia Praktyczna 2022;7(3):157-165.

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci. 2014; 19(2): 164–174.
    PubMed
  2. Yiannikourides A, Latunde-Dada GO. A short review of iron metabolism and pathophysiology of iron disorders. Medicines (Basel). 2019; 6(3).
    CrossRefPubMed
  3. Pasricha SR, Tye-Din J, Muckenthaler MU, et al. Iron deficiency. Lancet. 2021; 397(10270): 233–248.
    CrossRefPubMed
  4. Edison ES, Bajel A, Chandy M. Iron homeostasis: new players, newer insights. Eur J Haematol. 2008; 81(6): 411–424.
    CrossRefPubMed
  5. Barragán-Ibañez G, Santoyo-Sánchez A, Ramos-Peñafiel CO. Iron deficiency anaemia. Revista Médica del Hospital General de México. 2016; 79(2): 88–97.
    CrossRef
  6. Zimmer M, Sieroszewski P, Oszukowski P, et al. Polish Society of Gynecologists and Obstetricians recommendations on supplementation during pregnancy. Ginekol Pol. 2020; 91(10): 644–653.
    CrossRefPubMed
  7. Krawczyk P, Sioma-Markowska U. Nutrition quality of pregnant women based on body mass index and the content of selected nutrients and energy in the daily diet. Ginekol Pol. 2021 [Epub ahead of print].
    CrossRefPubMed
  8. Skrypnik D, Moszak M, Wender-Ozegowska E, et al. Comparison of Polish and international guidelines on diet supplements in pregnancy - review. Ginekol Pol. 2021; 92(4): 322–330.
    CrossRefPubMed
  9. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100): 1211–1259.
    CrossRefPubMed
  10. Levi M, Rosselli M, Simonetti M, et al. Epidemiology of iron deficiency anaemia in four European countries: a population-based study in primary care. Eur J Haematol. 2016; 97(6): 583–593.
    CrossRefPubMed
  11. WHO. Nutritional anaemias. Report of a WHO scientific group. WHO Technical Report Series, No. 405. 1968. https://apps.who.int/iris/handle/10665/40707 (13.05.2022).
  12. Kassebaum NJ. GBD 2013 Anemia Collaborators. The global burden of anemia. Hematol Oncol Clin North Am. 2016; 30(2): 247–308.
    CrossRefPubMed
  13. Levi M, Rosselli M, Simonetti M, et al. Epidemiology of iron deficiency anaemia in four European countries: a population-based study in primary care. Eur J Haematol. 2016; 97(6): 583–593.
    CrossRefPubMed
  14. WHO. Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia. 2008. WHO. Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia. 2008. (13.05.2022).
  15. NICE. Anaemia - iron deficiency: what causes it? https://cks.nice.org.uk/topics/anaemia-iron-deficiency/background-information/causes/. (13.05.2022).
  16. Miller JL. Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med. 2013; 3(7).
    CrossRefPubMed
  17. WHO A. Intermittent iron and folic acid supplementation during pregnancy in malaria- endemic areas. 2019.
  18. Breymann C, Breymann C. Anaemia Working Group. Iron deficiency anemia in pregnancy. Semin Hematol. 2015; 52(4): 339–347.
    CrossRefPubMed
  19. Russell RB, Green NS, Steiner CA, et al. Cost of hospitalization for preterm and low birth weight infants in the United States. Pediatrics. 2007; 120(1): e1–e9.
    CrossRefPubMed
  20. Colomer J, Colomer C, Gutierrez D, et al. Anaemia during pregnancy as a risk factor for infant iron deficiency: report from the Valencia Infant Anaemia Cohort (VIAC) study. Paediatr Perinat Epidemiol. 1990; 4(2): 196–204.
    CrossRefPubMed
  21. Lozoff B, Jimenez E, Smith JB. Double burden of iron deficiency in infancy and low socioeconomic status: a longitudinal analysis of cognitive test scores to age 19 years. Arch Pediatr Adolesc Med. 2006; 160(11): 1108–1113.
    CrossRefPubMed
  22. Haider BA, Olofin I, Wang M, et al. Nutrition Impact Model Study Group (anaemia). Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. BMJ. 2013; 346: f3443.
    CrossRefPubMed
  23. Vogel JP, Souza JP, Mori R, et al. Maternal complications and perinatal mortality: findings of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG BJOG-INT J OBSTET GY. 2014; 121: 76–88.
    CrossRef
  24. Janz TG, Johnson RL, Rubenstein SD. Anemia in the emergency department: evaluation and treatment. Emerg Med Pract. 2013; 15(11): 1–15; quiz 15.
    PubMed
  25. Murray-Kolb LE. Iron status and neuropsychological consequences in women of reproductive age: what do we know and where are we headed? J Nutr. 2011; 141(4): 747S–755S.
    CrossRefPubMed
  26. Muñoz M, Peña-Rosas JP, Robinson S, et al. Patient blood management in obstetrics: management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period: NATA consensus statement. Transfus Med. 2018; 28(1): 22–39.
    CrossRefPubMed
  27. Pavord S, Daru J, Prasannan N, et al. BSH Committee. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2020; 188(6): 819–830.
    CrossRefPubMed
  28. Radbruch L, Sabatowski R, Elsner F, et al. Validation of the German version of the brief fatigue inventory. J Pain Symptom Manage. 2003; 25(5): 449–458.
    CrossRefPubMed
  29. Brownlie T, Utermohlen V, Hinton PS, et al. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr. 2004; 79(3): 437–443.
    CrossRefPubMed
  30. Muñoz M, Gómez-Ramírez S, Besser M, et al. Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus. 2017; 15(5): 422–437.
    CrossRefPubMed
  31. Clark SF, Clark SF. Iron deficiency anemia. Nutr Clin Pract. 2008; 23(2): 128–141.
    CrossRefPubMed
  32. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011; 117(17): 4425–4433.
    CrossRefPubMed
  33. Karaskova E, Pospisilova D, Velganova-Veghova M, et al. Importance of hepcidin in the etiopathogenesis of anemia in inflammatory bowel disease. Dig Dis Sci. 2021; 66(10): 3263–3269.
    CrossRefPubMed
  34. Drabinski T, Zacharowski K, Meybohm P, et al. Estimating the epidemiological and economic impact of implementing preoperative anaemia measures in the german healthcare system: the health economic footprint of patient blood management. Adv Ther. 2020; 37(8): 3515–3536.
    CrossRefPubMed
  35. Fowler AJ, Ahmad T, Phull MK, et al. Meta-analysis of the association between preoperative anaemia and mortality after surgery. Br J Surg. 2015; 102(11): 1314–1324.
    CrossRefPubMed
  36. Wan S, Sparring V, Cabrales DA, et al. Clinical and budget impact of treating preoperative anemia in major orthopedic surgery - a retrospective observational study. J Arthroplasty. 2020; 35(11): 3084–3088.
    CrossRefPubMed
  37. Beattie WS, Karkouti K, Wijeysundera DN, et al. Risk associated with preoperative anemia in noncardiac surgery: a single-center cohort study. Anesthesiology. 2009; 110(3): 574–581.
    CrossRefPubMed
  38. Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet. 2011; 378(9800): 1396–1407.
    CrossRefPubMed
  39. Rössler J, Schoenrath F, Seifert B, et al. Iron deficiency is associated with higher mortality in patients undergoing cardiac surgery: a prospective study. Br J Anaesth. 2020; 124(1): 25–34.
    CrossRefPubMed
  40. Blackburn CW, Morrow KL, Tanenbaum JE, et al. Clinical outcomes associated with allogeneic red blood cell transfusions in spinal surgery: a systematic review. Global Spine J. 2019; 9(4): 434–445.
    CrossRefPubMed
  41. Filipescu D, Bănăţeanu R, Beuran M, et al. Perioperative patient blood management programme. Multidisciplinary recommendations from the . Rom J Anaesth Intensive Care. 2017; 24(2): 139–157.
    CrossRefPubMed
  42. Clevenger B, Gurusamy K, Klein AA, et al. Systematic review and meta-analysis of iron therapy in anaemic adults without chronic kidney disease: updated and abridged Cochrane review. Eur J Heart Fail. 2016; 18(7): 774–785.
    CrossRefPubMed
  43. Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015; 10(2): e0117383.
    CrossRefPubMed
  44. Desai N, Schofield N, Richards T. Perioperative patient blood management to improve outcomes. Anesth Analg. 2018; 127(5): 1211–1220.
    CrossRefPubMed
  45. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009; 69(6): 739–756.
    CrossRefPubMed
  46. FERRLECIT (sodium ferric gluconate complex in sucrose injection). https://products.sanofi.ca/en/ferrlecit.pdf (13.05.2022).
  47. Limited VPU. Ferinject (ferric carboxymaltose) summary of product characteristics 2015edicines org uk/emc/product. https://www.medicines.org.uk/emc/product/5910/smpc (13.05.2022).
  48. Cançado RD, Muñoz M. Intravenous iron therapy: how far have we come? Rev Bras Hematol Hemoter. 2011; 33(6): 461–469.
    CrossRefPubMed
  49. Pharma V. Iron products. https://www.viforpharma.com/en-gb/products/iron-products. (13.05.2022).
  50. Anker SD, Comin Colet J, Filippatos G, et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361(25): 2436–2448.
    CrossRefPubMed
  51. van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. EFFECT-HF Investigators. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017; 136(15): 1374–1383.
    CrossRefPubMed
  52. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008; 103(5): 1182–1192.
    CrossRefPubMed
  53. Evstatiev R, Alexeeva O, Bokemeyer B, et al. FERGI Study Group. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013; 11(3): 269–277.
    CrossRefPubMed
  54. Evstatiev R, Marteau P, Iqbal T, et al. FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011; 141(3): 846–853.e1.
    CrossRefPubMed
  55. Kulnigg-Dabsch S, Schmid W, Howaldt S, et al. Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Inflamm Bowel Dis. 2013; 19(8): 1609–1616.
    CrossRefPubMed
  56. Qunibi WY, Martinez C, Smith M, et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011; 26(5): 1599–1607.
    CrossRefPubMed
  57. Charytan C, Bernardo MV, Koch TA, et al. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Nephrol Dial Transplant. 2013; 28(4): 953–964.
    CrossRefPubMed
  58. Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014; 29(4): 833–842.
    CrossRefPubMed
  59. Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD Study Investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014; 29(11): 2075–2084.
    CrossRefPubMed
  60. Ikuta K, Hanashi H, Hirai K, et al. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study. Int J Hematol. 2019; 109(1): 41–49.
    CrossRefPubMed
  61. Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007; 110(2 Pt 1): 267–278.
    CrossRefPubMed
  62. Breymann C, Milman N, Mezzacasa A, et al. FER-ASAP investigators. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). J Perinat Med. 2017; 45(4): 443–453.
    CrossRefPubMed
  63. Seid MH, Derman RJ, Baker JB, et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008; 199(4): 435.e1–435.e7.
    CrossRefPubMed
  64. Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009; 49(12): 2719–2728.
    CrossRefPubMed
  65. Favrat B, Balck K, Breymann C, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One. 2014; 9(4): e94217.
    CrossRefPubMed
  66. Breymann C, Gliga F, Bejenariu C, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008; 101(1): 67–73.
    CrossRefPubMed
  67. Seid MH, Butcher AD, Chatwani A. Ferric carboxymaltose as treatment in women with iron-deficiency anemia. Anemia. 2017; 2017: 9642027.
    CrossRefPubMed
  68. Allen RP, Adler CH, Du W, et al. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 2011; 12(9): 906–913.
    CrossRefPubMed
  69. Trenkwalder C, Winkelmann J, Oertel W, et al. FCM-RLS Study Investigators. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. Mov Disord. 2017; 32(10): 1478–1482.
    CrossRefPubMed
  70. Hedenus M, Karlsson T, Ludwig H, et al. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med Oncol. 2014; 31(12): 302.
    CrossRefPubMed
  71. Bailie GR, Mason NA, Valaoras TG. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Hemodial Int. 2010; 14(1): 47–54.
    CrossRefPubMed
  72. Geisser P, Banké-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittelforschung. 2010; 60(6a): 362–372.
    CrossRefPubMed
  73. Barish CF, Koch T, Butcher A, et al. Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized, controlled trials. Anemia. 2012; 2012: 172104.
    CrossRefPubMed
  74. Hussain I, Bhoyroo J, Butcher A, et al. Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia. Anemia. 2013; 2013: 169107.
    CrossRefPubMed
  75. Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014; 54(2): 306–315.
    CrossRefPubMed
  76. Boomershine CS, Koch TA, Morris D. A blinded, randomized, placebo-controlled study to investigate the efficacy and safety of ferric carboxymaltose in iron-deficient patients with fibromyalgia. Rheumatol Ther. 2018; 5(1): 271–281.
    CrossRefPubMed
  77. Ponikowski P, Kirwan BA, Anker SD, et al. AFFIRM-AHF investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020; 396(10266): 1895–1904.
    CrossRefPubMed
  78. Aksan A, Schoepfer A, Juillerat P, et al. Iron formulations for the treatment of iron deficiency anemia in patients with inflammatory bowel disease: a cost-effectiveness analysis in switzerland. Adv Ther. 2021; 38(1): 660–677.
    CrossRefPubMed
  79. Filipescu D, Bănăţeanu R, Beuran M, et al. Perioperative patient blood management programme. Multidisciplinary recommendations from the . Rom J Anaesth Intensive Care. 2017; 24(2): 139–157.
    CrossRefPubMed
  80. Drabinski T, Zacharowski K, Meybohm P, et al. Estimating the epidemiological and economic impact of implementing preoperative anaemia measures in the german healthcare system: the health economic footprint of patient blood management. Adv Ther. 2020; 37(8): 3515–3536.
    CrossRefPubMed
  81. Breymann C, Milman N, Mezzacasa A, et al. FER-ASAP investigators. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). J Perinat Med. 2017; 45(4): 443–453.
    CrossRefPubMed
  82. Neiser S, Rentsch D, Dippon U, et al. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. Biometals. 2015; 28(4): 615–635.
    CrossRefPubMed
  83. Froessler B, Rueger AM, Connolly MP. Assessing the costs and benefits of perioperative iron deficiency anemia management with ferric carboxymaltose in Germany. Risk Manag Healthc Policy. 2018; 11: 77–82.
    CrossRefPubMed
  84. Froessler B, Gajic T, Dekker G, et al. Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy. Arch Gynecol Obstet. 2018; 298(1): 75–82.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023-2024 Via Medica Regulamin Polityka cookies Polityka prywatności Nota prawna